Grants and Contributions:

Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).

Dymedso Company has been working for several years in the research and development of new medicalx000D
technology, The FrequencerTM, to help patients affected by chronic respiratory diseases (CRDs) related tox000D
defective mucociliary clearance including cystic fibrosis (CF) and chronic bronchitis, among others.x000D
The FrequencerTM, manufactured by Dymedso Company, is a digitally controlled acoustic airway clearancex000D
point-of-care (POC) device that promotes bronchial drainage by inducing vibrations in the chest wall of thex000D
patient. The FrequencerTM provides a gentler and less painful form of therapy than the traditional "clappingx000D
method" or postural drainage. The current and older versions of this device have received certifications fromx000D
Health Canada, FDA, ISO 13485:2003, and UL for North America, Europe, Australia and New Zealand.x000D
Dymedso is planning to introduce a new technology of its sound-wave generation therapy that addresses somex000D
issues identified by patients and caregivers over the past years of use in clinical practice. The identified issuesx000D
involve ergonomic and performance limitations. For instance, the current version of the device is stillx000D
cumbersome for patient use. Thus, for more practical and effective use, the device needs to be optimized inx000D
terms of size, weight, and overall performance. We will carefully analyze each of the modules composing Thex000D
FrequencerTM including the sound-wave generator, the transducer, and the communication system to proposex000D
improvements for each of them. In addition, different types of sensors and feedback interfaces will bex000D
investigated for the new version in order to improve the effectiveness of this device.